Published August 30, 2025
| Version v1
Journal article
Open
The dual nature of inflammation: From essential host defense to driver of chronic disease: A review
Authors/Creators
- 1. Department of Pharmacognosy and Traditional Medicine, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
- 2. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
- 3. Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe 1 University, Awka, Anambra State, Nigeria.
- 4. Department of Pharmacognosy and Traditional Medicine, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University, Igbariam, Anambra State, Nigeria.
- 5. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Chukwuemeka Odumegwu Ojukwu University, Igbariam, Anambra State, Nigeria.
Description
Inflammation is a fundamental biological process with a dual nature, serving as an essential protective mechanism while also acting as a central driver of chronic disease when it becomes dysregulated. This review explores the critical distinction between acute, self-limiting inflammation and a persistent, damaging chronic state that underpins the pathogenesis of a wide range of pathologies, including cardiovascular disease, cancer, and autoimmune and metabolic disorders. The report examines the fundamental biology of the inflammatory response, detailing the roles of key cellular components and molecular mediators, such as the pro-inflammatory cytokines Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-alpha. It further highlights how the same inflammatory pathways can drive seemingly disparate diseases and discusses the profound role of chronic inflammation in post-COVID-19 conditions. Finally, the review outlines recent advancements in diagnostics, including the use of both established and novel biomarkers for personalized medicine, and highlights a new era of targeted therapeutic strategies, from specific cytokine inhibitors to innovative nanomedicine approaches, aimed at precisely managing the detrimental effects of inflammation.
Files
GSCARR-2025-0238.pdf
Files
(573.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:603bdf2768a661c0fe1c89f5c1c5615c
|
573.4 kB | Preview Download |